Speciality: Rheumatology
Description:
A warm welcome to all the medical professionals in this interesting session on the role of subcutaneous tocilizumab in managing rheumatoid arthritis.
Immunological pathways play a crucial role in disease management, especially in the case of rheumatological disease. Managing rheumatoid arthritis often becomes difficult due to its rate of progression and associated health issues.
Tocilizumab is a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody basically administered through intravenous infusion every 4 weeks. The treatment has been approved for patients with rheumatoid arthritis.
Due to the low risk of immunogenicity, the flexibility of IV and SC administration, and the convenience of administering weekly once, tocilizumab provides an effective treatment for severe, active, and progressive RA in adults.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
In leukemia, allogeneic HCT is beneficial following primary induction failure.
2.
Team finds broken 'brake' on cancer mutation machine.
3.
Omega Fatty Acid Changes Tied to Lower Proliferation Rate in Early Prostate Cancer
4.
Prostate cancer screening program beneficial in top decile of polygenic risk score
5.
Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.
1.
New Research on Craniopharyngioma
2.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
3.
A Closer Look at White Blood Cells in Urine: Uncovering the Causes and Treatments
4.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
5.
The Mysterious World of Petechiae: Exploring Causes and Treatments
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
4.
Navigating the Complexities of Ph Negative ALL - Part XV
5.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation